Curis, Inc.宣布以每股市场价格向现有专注于医疗保健领域的机构投资者进行850万美元的私募配售定价

LEXINGTON, Mass.

马萨诸塞州列克星敦

，

Oct. 16, 2026

2026年10月16日

/PRNewswire/ -- Curis, Inc. (Nasdaq:

/PRNewswire/ -- Curis, Inc.（纳斯达克：

CRIS

) ('Curis' or the 'Company'), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into securities purchase agreements with certain existing healthcare focused institutional investors for the purchase and sale of 16,666,680 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and common warrants to purchase up to 16,666,680 shares of common stock at an effective combined price of $0.51 per share (or pre-funded warrant) and accompanying common warrant (the 'Offering').

Curis（以下简称“Curis”或“公司”），一家专注于开发emavusertib（CA-4948）的生物技术公司，今日宣布已与某些现有的专注于医疗保健的机构投资者签订证券购买协议，以每股（或每份预付认股权证）0.51美元的有效综合价格，购买和出售16,666,680股普通股（或代替普通股的预付认股权证），以及附带最多可购买16,666,680股普通股的普通认股权证（以下简称“发行”）。

The common warrants have an exercise price of $0.60 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date. The pre-funded warrants have an exercise price of $0.01 per share and will be exercisable immediately until exercised in full.

普通权证的行权价格为每股0.60美元，将在发行六个月后可行权，并于发行日期起五年半后到期。预付资金权证的行权价格为每股0.01美元，将立即可行权，直至全部行权完毕。

。

The Company also has agreed that certain existing January 2026 warrants to purchase up to 1,126,676 shares of common stock at an exercise price of $15.00 per share and all of the August 2026 warrants to purchase up to 3,733,334 shares of common stock at an exercise price of $1.75 per share will be amended such that the existing January 2026 and August 2026 warrants will have a reduced exercise price of $0.60 per share..

本公司还同意，对某些现有的2026年1月认股权证（以每股15.00美元的行权价购买最多1,126,676股普通股）以及所有2026年8月认股权证（以每股1.75美元的行权价购买最多3,733,334股普通股）进行修订，使得现有的2026年1月和2026年8月认股权证的行权价降低至每股0.60美元。

The gross proceeds from the Offering are expected to be approximately $8.5 million, before deducting placement agents fees and other Offering expenses. The Company intends to use the net proceeds of this Offering to fund its research and development activities and for working capital and general corporate purposes.

在扣除配售代理费用及其他发行费用之前，本次发行的募集资金总额预计约为850万美元。公司拟将本次发行的净收益用于资助其研发活动，以及补充营运资金和满足一般公司用途。

Proceeds from the Offering are expected to be sufficient to fund operations through the Company's initial Chronic Lymphocytic Leukemia (CLL) data in 5-10 patients in December 2026. The Offering is expected to close on or about October 19, 2026, subject to market conditions and the satisfaction of customary closing conditions..

本次发行所得款项预计足以支持公司运营，直至2026年12月获得首批5至10名慢性淋巴细胞白血病（CLL）患者的初步数据。本次发行预计将于2026年10月19日左右完成，具体取决于市场状况及惯例交割条件的满足情况。

A.G.P./Alliance Global Partners is acting as the lead placement agent and Laidlaw & Company (UK) Ltd. is acting as co-placement agent in connection with the Offering.

A.G.P./Alliance Global Partners 担任本次发行的牵头配售代理，Laidlaw & Company (UK) Ltd. 担任联合配售代理。

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act') and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws.

前述证券的发售与销售系依据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条以及适用的州证券法项下的注册豁免规定进行，且该等证券未曾并将不会在初始阶段根据《证券法》或适用的州证券法办理注册。

Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Pursuant to the terms of the registration rights agreement entered into with the investors, the Company has agreed to file a registration statement with the U.S.

因此，除非依据生效的注册声明或适用《证券法》及适用的州证券法规定的注册要求豁免，否则不得在美国要约或出售该等证券。根据与投资者签订的注册权协议的条款，公司已同意向美国提交一份注册声明。

Securities and Exchange Commission (the 'SEC') covering the resale of the shares of common stock and the shares of common stock underlying the pre-funded warrants and common warrants sold in the Offering..

证券交易委员会（“SEC”）涉及本次发行中出售的普通股股份以及预融资权证和普通权证所对应的普通股股份的转售。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，也不得在任何州或其他司法管辖区进行这些证券的销售，如果在此类州或其他司法管辖区的证券法下，此类要约、招揽或销售在注册或资格认定之前是非法的。

About Curis, Inc.

关于 Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL).

Curis 是一家生物技术公司，专注于开发 emavusertib，这是一种可口服的小分子 IRAK4 和 FLT3 抑制剂。Emavusertib 目前正在两项临床试验中进行评估：一是在复发/难治性原发性中枢神经系统淋巴瘤（PCNSL）患者中，与 BTK 抑制剂伊布替尼联用的 TakeAim Lymphoma 1/2 期研究（CA-4948-101）；二是在慢性淋巴细胞白血病（CLL）患者中，与 BTK 抑制剂泽布替尼联用的 TakeAim CLL 2 期研究（CA-4948-203）。

The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL.

该公司在急性髓系白血病（AML）领域的单药治疗和联合治疗研究已基本完成，公司计划通过额外资金继续推进emavusertib在AML中的开发。Emavusertib已获得美国食品药品监督管理局授予的用于治疗原发性中枢神经系统淋巴瘤（PCNSL）、AML和骨髓增生异常综合征（MDS）的孤儿药资格认定，以及欧盟委员会授予的用于治疗PCNSL的孤儿药资格认定。

Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at .

Curis 通过其 2015 年与 Aurigene Discovery Technologies Limited 的合作，获得了 emavusertib（CA-4948）的独家许可。欲了解更多信息，请访问 Curis 网站：。

www.curis.com

。

Cautionary Note Regarding Forward-Looking Statements:

关于前瞻性陈述的警示说明：

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning Curis's expectations regarding the timing and completion of the PIPE financing, the intended use of the proceeds from the PIPE financing and statements regarding initial CLL data. Forward-looking statements may contain the words 'believes,' 'expects,' 'anticipates,' 'plans,' 'intends,' 'seeks,' 'estimates,' 'assumes,' 'predicts,' 'projects,' 'targets,' 'will,' 'may,' 'would,' 'could,' 'should,' 'likelihood', 'continue,' 'potential,' 'opportunity,' 'focus,' 'strategy,' 'mission,' or similar expressions.

本新闻稿包含经修订的1995年美国《私人证券诉讼改革法》所定义的“前瞻性陈述”，包括但不限于关于Curis公司对PIPE融资的时间和完成的预期、PIPE融资所得款项的预期用途以及关于初始CLL数据的陈述。前瞻性陈述可能包含“相信”、“期望”、“预计”、“计划”、“打算”、“寻求”、“估计”、“假设”、“预测”、“规划”、“目标”、“将”、“可能”、“会”、“可以”、“应该”、“可能性”、“继续”、“潜力”、“机会”、“聚焦”、“战略”、“使命”或类似表述。

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all.

这些前瞻性陈述并非对未来表现的保证，涉及风险、不确定性、假设及其他重要因素，可能导致实际结果与前述前瞻性陈述所指示的结果存在重大差异。Curis 在其药物开发项目中可能会遭遇不利结果、延迟和/或失败，可能无法在其预期的时间框架内（甚至根本不能）成功推进其候选药物的开发。

Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials.

Curis的候选药物可能会导致意外的毒性反应，在临床研究中未能展现出足够的安全性和有效性，和/或可能永远无法获得商业化所需的必要监管批准。在Curis候选药物的临床前研究和早期临床试验中观察到的有利结果可能在后期试验中无法重现。

Curis is dependent on the success of emavusertib and any delays in the development of emavusertib could have a material adverse effect on its business. There can be no guarantee that the collaboration agreement with Aurigene or the CRADA with NCI will continue for .

Curis 的成功依赖于 emavusertib，emavusertib 开发的任何延误都可能对其业务产生重大不利影响。无法保证与 Aurigene 的合作协议或与 NCI 的 CRADA 将会持续。

SOURCE Curis, Inc.

来源：Curis, Inc.

二十一

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示